, Volume 16, Issue 3, pp 216-221
Date: 08 Aug 2010

Effect of traditional and integrative regimens on quality of life and early renal impairment in elderly patients with isolated systolic hypertension

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Objective

To observe the effect of Chinese medical regimen and integrative medical regimen on quality of life and early renal impairment in elderly patients with isolated systolic hypertension (EISH).

Methods

A multi-center, randomized, double-blinded controlled trail was adopted. A total of 270 cases of EISH were randomly divided into 3 groups: Chinese medicine group (CM), combination group and Western medicine group (WM). The course of treatment was 4 weeks. The clinical blood pressure, integral of quality of life (SF-36 scale), immunoglubin G (IgG), microalbumin (mALB), β2-microglobulin (β2-MG), transferrin (TRF) and N-acetyl-β′-D-glucosa-minidase (NAG) in urine were determined before and after the treatment.

Results

After treatment, systolic blood pressure depressed significantly in each group (P<0.05), and the combination group was superior to CM or WM group in depressing SBP (P<0.05); in each group, integral of quality of life improved in different degree, and combination group was superior to WM group in all 8 dimensions (P<0.05). The level of mALB and β2-MG in urine decreased in all groups (P<0.05), and the combination group was superior to CM group or WM group in decreasing mALB (P<0.05).

Conclusions

Chinese medical regimen has affirmative effect in treating EISH patients, and could lower the systolic blood pressure, improve quality of life and early renal impairment of the patients, and integrative medical regimen has superiority on account of cooperation, and deserves further study.

Supported by “Eleventh Five-Year” National Science and Technology Support Program of Chinese Medicine Treatment of Common Diseases Project (No. 2007BAI20B07); Science and Technology Research Projects of Capital Medical Development Fund, (No. 03 II 01)